MarketPR
CLFCleveland-Cliffs reports Q3 2026 net income of $165 millionOct 21MKSIMKS Inc. agrees to sell Ophir Optics to TTM Technologies for $650 millionOct 21SLNMerck KGaA to Acquire Silence Therapeutics in $1.3 Billion Cash DealOct 21SLGNSilgan Forms Metal Packaging Partnership With AIP FundsOct 21GEGE Aerospace raises 2026 guidance on record engine ordersOct 21INSMInsmed adds Sanofi and Verily executives to boardOct 21MAMastercard Q2 Revenue Beats Gross Dollar Volume GrowthOct 21REGULATORYKiffin blames SEC schedule for LSU strugglesOct 21EARNINGSNextDC shares plunge 39.5% after slashing earnings forecastOct 21NLYAnnaly Capital Management reports $0.80 EAD per share for third quarterOct 21CLFCleveland-Cliffs reports Q3 2026 net income of $165 millionOct 21MKSIMKS Inc. agrees to sell Ophir Optics to TTM Technologies for $650 millionOct 21SLNMerck KGaA to Acquire Silence Therapeutics in $1.3 Billion Cash DealOct 21SLGNSilgan Forms Metal Packaging Partnership With AIP FundsOct 21GEGE Aerospace raises 2026 guidance on record engine ordersOct 21INSMInsmed adds Sanofi and Verily executives to boardOct 21MAMastercard Q2 Revenue Beats Gross Dollar Volume GrowthOct 21REGULATORYKiffin blames SEC schedule for LSU strugglesOct 21EARNINGSNextDC shares plunge 39.5% after slashing earnings forecastOct 21NLYAnnaly Capital Management reports $0.80 EAD per share for third quarterOct 21
NewsDeals

Jazz Pharmaceuticals (JAZZ) to acquire Actio Biosciences in deal valued at up to $1.3 billion

A $820 million upfront payment sets the price of entry. Jazz Pharmaceuticals has agreed to acquire San Diego-based Actio Biosciences for up to $1.3 billion, adding a potential first-in-class treatment for KCNT1-related epilepsy to a neuroscience portfolio that already houses Epidiolex. The two companies expect the transaction to close in the fourth quarter of 2026.

By Renata OstrowskiNewsroomAugust 12, 20262 min read
Share

Key takeaways

  • Jazz Pharmaceuticals has agreed to acquire San Diego-based Actio Biosciences for up to $1.3 billion, with $820 million paid upfront at close and $500 million tied to regulatory and sales milestones.
  • The deal centers on Actio's lead program ABS-1230, a potential first-in-class treatment for KCNT1-related epilepsy that blocks overactive potassium ion channels.
  • Jazz estimates KCNT1-related epilepsy affects roughly 2,500 people in the United States with no approved therapies, and severe cases can involve hundreds of seizures per day.
  • The transaction is expected to close in the fourth quarter of 2026 and will be funded with cash on hand and existing financing facilities.
  • At closing, Actio will spin out a separate private entity to house its ion channel inhibitor for Charcot-Marie-Tooth disease, with Jazz retaining a minority stake.

A $820 million upfront payment sets the price of entry. Jazz Pharmaceuticals has agreed to acquire San Diego-based Actio Biosciences for up to $1.3 billion, adding a potential first-in-class treatment for KCNT1-related epilepsy to a neuroscience portfolio that already houses Epidiolex. The two companies expect the transaction to close in the fourth quarter of 2026.

Deal structure and the balance sheet

The full figure carries conditionality: Actio collects $820 million at close, with the remaining $500 million tied to regulatory and sales milestones. Jazz said it will fund the acquisition with cash on hand and draws on existing financing facilities. As of June 30, the company held $2.2 billion in cash, cash equivalents and investments, carried $4.4 billion in long-term debt, and had $885 million in undrawn revolving credit capacity. Concurrent with closing, Actio will spin out a separate private entity to house its ion channel inhibitor for Charcot-Marie-Tooth disease, with Jazz retaining a minority stake in that vehicle.

The asset: ABS-1230 and the KCNT1 indication

Actio's lead program, ABS-1230, targets KCNT1-related epilepsy, a disease Jazz estimates affects roughly 2,500 people in the United States with no approved therapies. In severe cases, patients can experience hundreds of seizures per day. The drug works by blocking overactive potassium ion channels. A proof-of-concept trial produced what the companies described as "meaningful seizure reductions." ABS-1230 is now enrolling approximately 55 participants in a study that could support a U.S. approval application. Actio also sees potential to test it in more prevalent genetic epilepsies, which would expand the addressable population.

A record quarter and a broader M&A pattern

Jazz CEO Renee Gala characterized the move as building on the Epidiolex franchise and deepening the company's position in rare and severe epilepsies. The most recent quarter produced $1.2 billion in total revenue, a 16% year-over-year gain and a company record. The deal also lands inside a heated stretch for venture-backed biotech acquisitions: HSBC Innovation Banking counted 19 such deals in the first half of 2026, already more than any full year in the prior five, with median deal value reaching $950 million, roughly three times the levels seen in the early 2020s.

What to watch

TD Cowen analyst Joseph Thome wrote that the acquisition adds "meaningful pipeline optionality" for Jazz. His team wants patient-level data, a timeline for results from the 55-participant study, and clarity on the regulatory package before "assigning material value" to ABS-1230. That study readout is the first hard milestone on the tape.

Related reading

About this story

Filed by the newsroom of MarketPR on August 12, 2026. Source: finance.yahoo.com. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Deals

Freddy Peralta joins Bob Gibson in rare 10-start pitching streak

Tampa Bay Rays ace Freddy Peralta has completed a 10-start sequence in which he allowed one run or fewer in each game, a feat accomplished only twice in the last 114 years. According to Opta STATS, Peralta pitched more than 50 innings…

Desmond Choi2 min read
02Deals

JNJ stock slips 6% despite Q3 earnings beat, MedTech misses

Johnson & Johnson shares (JNJ) initially dropped nearly 6% on Oct. 13 following the release of third-quarter 2026 results. Although the company exceeded Wall Street estimates on both top and bottom lines, the stock's immediate decline was…

Miles Broadbent2 min read
03Deals

Brady Tkachuk records first back-to-back hat tricks since 2024

Florida Panthers forward Brady Tkachuk scored hat tricks in consecutive victories over the Columbus Blue Jackets and Vancouver Canucks, marking the first time an American player has achieved the feat since Auston Matthews in 2024. The…

Grant Halloran2 min read

Frequently asked

How much is Jazz paying upfront versus in milestones?

Actio Biosciences receives $820 million at close, with the remaining $500 million contingent on regulatory and sales milestones, for a total deal value of up to $1.3 billion.

What is ABS-1230 and what does it treat?

ABS-1230 is Actio's lead program targeting KCNT1-related epilepsy; it works by blocking overactive potassium ion channels and produced 'meaningful seizure reductions' in a proof-of-concept trial.

What is the next key milestone for the drug?

ABS-1230 is enrolling approximately 55 participants in a study that could support a U.S. approval application, and its readout is the first hard milestone analysts are watching.

How is Jazz financing the acquisition?

Jazz will fund the deal with cash on hand and draws on existing financing facilities; as of June 30 it held $2.2 billion in cash and investments and had $885 million in undrawn revolving credit capacity.

How does this deal fit Jazz's broader business?

It builds on Jazz's Epidiolex franchise and its position in rare and severe epilepsies, coming after a company-record quarter of $1.2 billion in revenue, up 16% year-over-year.